Intravenous drug users and hepatitis C treatment Higgs P et al. 517 Infect Dis. 2009;49(4):561-73. 7. Belfiori B, Ciliegi P, Chiodera A, Bacosi D, Tosti A, Baldelli F, et al. Peginterferon plus Ribavirin for chronic hepatitis C in opiate addicts on methadone/buprenorphine maintenance therapy. Digest Liver Dis. 2009;41(4):303-7. 8. Dore GJ, Hellard M, Matthews GV, Grebely J, Haber PS, Petoumenos K, et al. Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Gastroenterology. 2010;138(1):123-35 e1-2. 9. Ebner N, Wanner C, Winklbaur B, Matzenauer C, Jachmann CA, Thau K, et al. Retention rate and side effects in a prospective trial on hepatitis C treatment with pegylated interferon alpha- 2a and ribavirin in opioid-dependent patients. Addict Biol. 2009;14(2):227-37. 10. Litwin AH, Harris KA, Nahvi S, Zamor PJ, Soloway IJ, Tenore PL, et al. Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program. J Subst Abuse Treat. 2009;37(1):32-40. 11. Morrill JA, Shrestha M, Grant RW. Barriers to the treatment of hepatitis C. Patient, provider, and system factors. J Gen Intern Med. 2005;20(8):754-8. 12. Sylvestre D, Loftis J, Hauser P, Genser S, Cesari H, Borek N, et al. Co-occurring hepatitis C, substance use, and psychiatric illness: Treatment issues and developing integrated models of care. J Urban Health. 2004;81(4):719-34. 13. Watson B, Conigrave KM, Wallace C, Whitfield JB, Wurst F, Haber PS. Hazardous alcohol consumption and other barriers to antiviral treatment among hepatitis C positive people receiving opioid maintenance treatment. Drug Alcohol Rev. 2007;26(3):231-9. 14. Falck-Ytter Y, Kale H, Mullen KD, Sarbah SA, Sorescu L, McCullough AJ. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med. 2002;136(4):288-92. 15. Fleming CA, Craven DE, Thornton D, Tumilty S, Nunes D. Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment. Clin Infect Dis. 2003;36(1):97-100. 16. Hagan H, Latka MH, Campbell JV, Golub ET, Garfein RS, Thomas DA, et al. Eligibility for treatment of hepatitis C virus infection among young injection drug users in 3 US cities. Clin Infect Dis. 2006;42(5):669-72. 17. Hatem C, Minello A, Bresson-Hadni S, Jooste V, Evrard P, Obert B, et al. Is the management of hepatitis C patients appropriate? A population-based study. Aliment Pharmacol Ther. 2005;21(8):1007- 15. 18. Muir AJ, Provenzale D. A descriptive evaluation of eligibility for therapy among veterans with chronic hepatitis C virus infection. J Clin Gastroenterol. 2002;34(3):268-71. 19. Restrepo A, Johnson TC, Widjaja D, Yarmus L, Meyer K, Clain DJ, et al. The rate of treatment of chronic hepatitis C in patients co-infected with HIV in an urban medical centre. J Viral Hepat. 2005;12(1):86-90. 20. Stoove MA, Gifford SM, Dore GJ. The impact of injecting drug use status on hepatitis C-related referral and treatment. Drug Alcohol Depend. 2005;77(1):81-6. 21. Yawn BP, Wollan P, Gazzuola L, Kim WR. Diagnosis and 10-year follow-up of a community-based hepatitis C cohort. J Fam Pract. 2002;51(2):135-40. 22. Grebely J, Raffa JD, Meagher C, Duncan F, Genoway KA, Khara M, et al. Directly observed therapy for the treatment of hepatitis C virus infection in current and former injection drug users. J Gastroenterol Hepatol. 2007;22(9):1519-25. 23. Sylvestre DL, Litwin AH, Clements BJ, Gourevitch MN. The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone. J Subst Abuse Treat. 2005;29(3):159-65. 24. Belfiori B, Chiodera A, Ciliegi P, Tosti A, Baldelli F, Stagni G, et al. Treatment for hepatitis C virus in injection drug users on opioid replacement therapy: a prospective multicentre study. Eur J Gastroenterol Hepatol. 2007;19(8):731-2. 25. Sylvestre DL, Clements BJ. Adherence to hepatitis C treatment in recovering heroin users maintained on methadone. Eur J Gastroenterol Hepatol. 2007;19(9):741-7. 26. Jeffrey GP, MacQuillan G, Chua F, Galhenage S, Bull J, Young E, et al. Hepatitis C virus eradication in intravenous drug users maintained with subcutaneous naltrexone implants. Hepatology. 2007;45(1):111-7. 27. Dalgard O. Follow-Up Studies of Treatment for Hepatitis C Virus Infection among Injection Drug Users. Clin Infect Dis. 2005;40(Suppl 5):S336-8. 28. Asselah T, Vidaud D, Doloy A, Boyer N, Martinot M, Vidaud M, et al. Second infection with a different hepatitis C virus genotype in a intravenous drug user during interferon therapy. Gut. 2003;52(6):900-2. 29. Backmund M, Meyer K, Edlin BR. Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users. Clin Infect Dis. 2004;39(10):1540-3. 30. Dalgard O, Bjoro K, Hellum K, Myrvang B, Skaug K, Gutigard B, et al. Treatment of chronic hepatitis C in injecting drug users: 5 years’ follow-up. Eur Addict Res. 2002;8(1):45-9. 31. Grebely J, Knight E, Ngai T, Genoway KA, Raffa JD, Storms M, et al. Reinfection with hepatitis C virus following sustained virological response in injection drug users. J Gastroenterol Hepatol. 2010;25(7):1281-4. 32. Aitken CK, Lewis J, Tracy SL, Spelman T, Bowden DS, Bharadwaj M, et al. High incidence of hepatitis C virus reinfection in a cohort of injecting drug users. Hepatology. 2008;48(6):1746-52. 33. van de Laar TJ, Molenkamp R, van den Berg C, Schinkel J, Beld MG, Prins M, et al. Frequent HCV reinfection and superinfection in a cohort of injecting drug users in Amsterdam. J Hepatol. 2009;51(4):667-74. 34. Fujita N, Sugimoto R, Urawa N, Araki J, Mifuji R, Yamamoto M, et al. Hepatic iron accumulation is associated with disease progression and resistance to interferon/ribavirin combination therapy in chronic hepatitis C. J Gastroenterol Hepatol. 2007;22(11):1886-93. 35. Izumi N, Enomoto N, Uchihara M, Murakami T, Ono K, Noguchi O, et al. Hepatic iron contents and response to interferon-alpha in patients with chronic hepatitis C. Relationship to genotypes of hepatitis C virus. Dig Dis Sci. 1996;41(5):989-94. 36. Ono K, Sata M, Murashima S, Fukuizumi K, Suzuki H, Tanikawa K. Biological responses to administered interferon in alcoholics. Alcohol Clin Exp Res. 1996;20(9):1560-3. 37. Zylberberg H, Fontaine H, Thepot V, Nalpas B, Brechot C, Pol S. Triggering of acute alcoholic hepatitis by alpha-interferon therapy. J Hepatol. 1999;30(4):722-5. 38. Anand BS, Thornby J. Alcohol has no effect on hepatitis C virus replication: a meta-analysis. Gut. 2005;54(10):1468-72. 39. Bhattacharya R, Shuhart MC. Hepatitis C and alcohol: interactions, outcomes, and implications. J Clin Gastroenterol. 2003;36(3):242-52. 40. Cooper CL. Obstacles to successful HCV treatment in substance addicted patients. J Addict Dis. 2008;27(2):61-8. 41. Loguercio C, Di Pierro M, Di Marino MP, Federico A, Disalvo D, Crafa E, et al. Drinking habits of subjects with hepatitis C virus-related chronic liver disease: prevalence and effect on clinical, virological and pathological aspects. Alcohol Alcohol. 2000;35(3):296-301. 42. Oshita M, Hayashi N, Kasahara A, Hagiwara H, Mita E, Naito M, et al. Increased serum hepatitis C virus RNA levels among alcoholic patients with chronic hepatitis C. Hepatology. 1994;20(5):1115-20. 43. Chang A, Skole K, Gautam M, Schmutz J, Black M, Thomas R, et al. The impact of past alcohol use on treatment response rates in patients with chronic hepatitis C. Aliment Pharmacol Ther. 2005;22(8):701-6. 44. Chen CM, Yoon YH, Yi HY, Lucas DL. Alcohol and hepatitis C mortality among males and females in the United States: a life table analysis. Alcohol Clin Exp Res. 2007;31(2):285-92. 45. Mochida S, Ohnishi K, Matsuo S, Kakihara K, Fujiwara K. Effect of alcohol intake on the efficacy of interferon therapy in patients with chronic hepatitis C as evaluated by multivariate logistic regression analysis. Alcohol Clin Exp Res. 1996;20(9 Suppl):371A- 7A. 46. Tabone M, Sidoli L, Laudi C, Pellegrino S, Rocca G, Della Monica P, et al. Alcohol abstinence does not offset the strong negative effect of lifetime alcohol consumption on the outcome of interferon therapy. J Viral Hepat. 2002;9(4):288-94. Hepat Mon. 2011;11(7):513-518